title: Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome.
abstract: OBJECTIVE
  Activation of coagulation and inflammation are parts of the innate host response to infection that may contribute to organ dysfunction and death when control of these systems is compromised. Thus, functional single nucleotide polymorphisms within candidate genes of the inflammation and coagulation cascade are possible factors which may influence severity and/or mortality in acute respiratory distress syndrome. The aim of this study was to investigate whether the factor V Leiden mutation (Arg506Gln) is associated with altered severity and/or mortality in acute respiratory distress syndrome.
  
  
  METHODS
  Retrospective cohort, genetic association study.
  
  
  METHODS
  Tertiary care intensive care unit.
  
  
  METHODS
  Adults (white Germans) with acute respiratory distress syndrome (n = 106).
  
  
  METHODS
  Genotyping for the factor V Leiden mutation.
  
  
  RESULTS
  Using Kaplan-Meier estimates to compare outcome, 30-day survival was significantly associated with the factor V Leiden mutation (p = .049). Thirty-day survival rates were 100% for Arg/Gln (n = 7) genotypes but only 58% for Arg/Arg (n = 99) genotypes, respectively.
  
  
  CONCLUSIONS
  We show for the first time that a heterozygous factor V Leiden genotype is associated with improved 30-day survival in patients with acute respiratory distress syndrome.
authors.affiliation: Klinik für Anästhesiologie und Intensivmedizin, Universität Duisburg-Essen, Universitätsklinikum Essen, Essen, Germany. michael.adamzik@uk-essen.de
authors.forename: Michael
authors.initials: M
authors.lastname: Adamzik
authors.forename: Ulrich H
authors.initials: UH
authors.lastname: Frey
authors.forename: Kathrin
authors.initials: K
authors.lastname: Riemann
authors.forename: Stephan
authors.initials: S
authors.lastname: Sixt
authors.forename: Nils
authors.initials: N
authors.lastname: Lehmann
authors.forename: Winfried
authors.initials: W
authors.lastname: Siffert
authors.forename: Jürgen
authors.initials: J
authors.lastname: Peters
mesh_terms: D018806:APACHE; D020016:Activated Protein C Resistance / Q000235:genetics*; D000328:Adult; D001120:Arginine / Q000235:genetics; D015331:Cohort Studies; D005165:Factor V / Q000235:genetics*; D005260:Female; D005838:Genotype; D005973:Glutamine / Q000235:genetics; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017354:Point Mutation / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012128:Respiratory Distress Syndrome / Q000235:genetics* / Q000401:mortality; D012189:Retrospective Studies
chemical_list: C095381:factor V Leiden; D005973:Glutamine; D005165:Factor V; D001120:Arginine